Latest News

Enrollment Complete for Phase 2 Alzheimer Trial of Low-Dose Interleukin-2
Enrollment Complete for Phase 2 Alzheimer Trial of Low-Dose Interleukin-2

May 24th 2024

The double-blind, placebo-controlled trial, which includes 2 dosing regimens of COYA 302, is expected to have topline data reported later this summer.

Post-AAN Perspectives: Recapping Major Areas of Growth in Neurology
Post-AAN Perspectives: Recapping Major Areas of Growth in Neurology

May 23rd 2024

Building a “Dementia Garden” for Cognitive Benefits During the Springtime
Building a “Dementia Garden” for Cognitive Benefits During the Springtime

May 23rd 2024

Duchenne Agent DYNE-251 Demonstrates Functional Improvement in Phase 1/2 DELIVER Trial
Duchenne Agent DYNE-251 Demonstrates Functional Improvement in Phase 1/2 DELIVER Trial

May 23rd 2024

DYNE-101 Continues to Show Success in Early-Stage ACHIEVE Trial of Myotonic Dystrophy
DYNE-101 Continues to Show Success in Early-Stage ACHIEVE Trial of Myotonic Dystrophy

May 23rd 2024

Coverage of the 2024 American Academy of Neurology Annual Meeting

Get the latest data and clinical news updates, as well as interviews with experts, straight from the conference floor of the AAN Annual Meeting.

AAN 2024

Conference Coverage

View All
Post-AAN Perspectives: Recapping Major Areas of Growth in Neurology
Post-AAN Perspectives: Recapping Major Areas of Growth in Neurology

May 23rd 2024

NeuroVoices: Katherine Peters, PhD, on Vorasidenib’s Impact on Quality of Life, Neurocognition, and Seizures in the Treatment of Gliomas
NeuroVoices: Katherine Peters, PhD, on Vorasidenib’s Impact on Quality of Life, Neurocognition, and Seizures in the Treatment of Gliomas

May 22nd 2024

Frederic Schaper, MD, PhD  (Credit: Harvard Catalyst)
Exploring the Association Between Brain Lesions and Takotsubo Syndrome

May 21st 2024

Susan W. Broner, MD  (Credit: Weill Cornell Medicine)
Essentials for Treating Headache as a General Neurologist

May 19th 2024

Video Series
Video Interviews
Podcasts

Most Recent

© 2024 MJH Life Sciences

All rights reserved.